Mining the molecules that matter

Pragma Bio’s AI-enabled biology-first approach mines an untapped clinically-relevant source of novel small molecules to target the gut-immune axis for diverse clinical applications.

The Problem

Current drug discovery methods primarily rely on target-first approaches and synthetic molecule libraries that are associated with high clinical trial failure rates due to lack of efficacy.

The Pragma Bio Solution

At Pragma Bio, we discover new medicines using our biology-first approach that :

  • Mines a clinically-relevant source of small molecules 
  • Uses phenotypic screens to uncover new disease-modifying pathways and targets
  • De-risks efficacy early in development

The Opportunity

The Gut-Immune Axis (GIA) plays an essential role in health and disease by coordinating interactions between the immune system and gut microbes.

This GIA coordination is mediated via small molecules produced by gut-residing microbes. The instruction manuals for these immune-regulating molecules are the  Biosynthetic Gene Clusters (BGCs) found on the microbial genome.

The small molecules made using the BGC instruction manual have co-evolved with humans and can be the source of many new medicines.

Our Platform - PIKASO

At Pragma Bio, we have built a biology-first, AI-enabled platform for mining, making, and testing novel gut-derived small molecules to create effective new medicines.

1

Bioinformatics & AI

Mine clinically-relevant BGCs for specific diseases using Real World Evidence (RWE) and multi-omics datasets.

2

SynBio & MedChem

Make, analyze, and derivatize those BGCs and their small molecule products using cutting-edge synthetic biology and chemistry tools.

3

Pharmacology

Test molecules in models of disease biology to select candidates for further optimization and characterization and to decipher the molecular target and mechanism of action.

What makes us different

End-to-end data-to-molecule discovery pipeline powered by best-in-class BGC database

Promoting speed, standardization, failing-fast

Proprietary expertise in small molecule synthesis

Generating patentable novel molecules for New Chemical Entity (NCE) optimization

De-risked starting points for novel medicines

Mining a source of naturally evolved molecules enriched with immune system modulators

Automated, AI-based, adaptive BGC platform

Building the smartest, ever-evolving BGC-to-molecule pipeline and database mining tools

Our team

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

Stuart Chaffee, PhD, MBA

,

Serial Founder, CBO/CFO

Nicholas Shekerdemian, B.S.

,

Founding Partner, The Venture Collective

Raquel Izumi, PhD

,

Founder, Acerta Pharma

Kareem Barghouti, MBA

,

Co-Founder,

Chief Executive Officer & President

Mohamed Donia, PhD

,

Scientific Co-Founder,

Chief Scientific Officer

Abbas Kazimi, MS

,

CBO, Nimbus Tx

Grazia Piizzi, PhD

,

Biopharma/Biotech Executive, Small Molecule Discovery

Ayin Vala, MS

,

Co-Founder,

Chief AI Officer

Elaine Stracker, JD, PhD

,

General Counsel & EVP, Pharmacyclics

Peter McCaffrey, MD

,

Co-Founder,

Chief Technology Officer

Orly Levitan, PhD

,

VP Partnerships and Business Development

Philip Jones, PhD

,

VP for Therapeutics Discovery, MD Anderson Cancer Center

Mark Ashwell, PhD

,

Head of Chemistry

Milad Alucozai, MSc, MPH, DrPH

,

Serial Biotech Founder, Managing Director at BoxOne Ventures

Riccardo Guidi, PhD

,

Head of Pharmacology

Mohan Iyer, MBA

,

General Partner, SOSV/IndieBio

Jesus Barajas, PhD

,

Head of Synthetic Biology

Ken Blount, PhD

,

CSO, Rebiotix & VP Microbiome Research, Ferring Pharmaceuticals

Lanying Ma, PhD

,

Sr. Bioinformaticist II

Todd DeSantis, MS

,

Founder, Second Genome

Jordan Berg, PhD

,

Sr. Data Scientist I

Caitlyn Bonilla, B.S.

,

Lead Automation Engineer

Daniela Vega, PhD

,

Scientist I

Varun Bhadkamkar, PhD

,

Scientist I

Nehal Hegde, B.S.

,

Research Assistant

Our team

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

Nicholas Shekerdemian, B.S.

,

Founding Partner, The Venture Collective

Stuart Chaffee, PhD, MBA

,

Serial Founder, CBO/CFO

Kareem Barghouti, MBA

,

Co-Founder,

Chief Executive Officer & President

Raquel Izumi, PhD

,

Founder, Acerta Pharma

Mohamed Donia, PhD

,

Scientific Co-Founder,

Chief Scientific Officer

Abbas Kazimi, MS

,

CBO, Nimbus Tx

Ayin Vala, MS

,

Co-Founder,

Chief AI Officer

Grazia Piizzi, PhD

,

Biopharma/Biotech Executive, Small Molecule Discovery

Our Investors

We are proudly supported by top tier investors and strategic partners

Partner with us

Our network includes some of the leading biopharma and research organizations. Reach out to explore possible collaborations and synergies!

Partner with us
By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.